| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
77,230,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. AT-007 is a central nervous system penetrant ARI that Co. is developing for the treatment of metabolic diseases, including Galactosemia, a pediatric metabolic disease that affects how the body processes a simple sugar called galactose. AT-001 is an ARI with systemic exposure and peripheral nerve permeability that Co. is developing for the treatment of diabetic cardiomyopathy. AT-003 is an ARI designed to cross through the back of the eye when dosed orally for the treatment of diabetic retinopathy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
30,000 |
30,000 |
3,691,409 |
| Total Buy Value |
$0 |
$65,367 |
$65,367 |
$3,658,451 |
| Total People Bought |
0 |
1 |
1 |
3 |
| Total Buy Transactions |
0 |
1 |
1 |
5 |
| Total Shares Sold |
506,975 |
1,088,491 |
1,224,775 |
1,252,098 |
| Total Sell Value |
$2,732,596 |
$4,098,859 |
$4,466,825 |
$4,492,358 |
| Total People Sold |
4 |
6 |
6 |
7 |
| Total Sell Transactions |
4 |
11 |
14 |
18 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Alexandria Equities No. 7, Llc |
10% Owner |
– – • |
2022-06-27 |
4 |
B |
$1.00 |
$3,500,000 |
I/I |
3,500,000 |
4,555,077 |
1.5 |
- |
|
| Mahadevan Chids |
See Remarks |
• – – |
2022-05-16 |
4 |
S |
$1.65 |
$1,493 |
D/D |
(905) |
9,800 |
|
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2022-03-23 |
4 |
B |
$1.97 |
$59,100 |
D/D |
30,000 |
160,909 |
2.74 |
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2022-03-22 |
4 |
B |
$1.98 |
$43,483 |
D/D |
21,961 |
130,909 |
2.74 |
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2022-03-21 |
4 |
B |
$1.85 |
$23,214 |
D/D |
12,548 |
108,948 |
2.74 |
- |
|
| Ortega Steven A. |
Principal Accounting OfficerOf |
• – – |
2022-03-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,323 |
|
- |
|
| Alexandria Equities No. 7, Llc |
10% Owner |
– – • |
2022-02-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(300,000) |
943,977 |
|
- |
|
| Alexandria Equities No. 7, Llc |
10% Owner |
– – • |
2022-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
300,000 |
2,490,077 |
|
- |
|
| Shendelman Shoshana |
President and CEO |
• • • |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
120,900 |
606,086 |
|
- |
|
| Hansard Adam |
Chief Commercial Officer |
• – – |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
31,700 |
96,970 |
|
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
48,200 |
96,400 |
|
- |
|
| Silberstein Charles |
Chief Financial Officer |
• – – |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
47,900 |
183,603 |
|
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
48,200 |
48,200 |
|
- |
|
| Silberstein Charles |
Chief Financial Officer |
• – – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
47,900 |
135,703 |
|
- |
|
| Shendelman Shoshana |
President and CEO |
• • • |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
120,900 |
485,186 |
|
- |
|
| Hansard Adam |
Chief Commercial Officer |
• – – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
31,700 |
65,270 |
|
- |
|
| Shendelman Shoshana |
President and CEO |
• • • |
2021-09-14 |
4 |
B |
$14.49 |
$134,740 |
D/D |
9,300 |
364,286 |
3.23 |
- |
|
| Shendelman Shoshana |
President and CEO |
• • • |
2021-09-13 |
4 |
B |
$14.69 |
$10,298 |
D/D |
701 |
354,986 |
3.15 |
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2021-08-10 |
4 |
AS |
$16.35 |
$13,080 |
D/D |
(800) |
0 |
|
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2021-08-10 |
4 |
S |
$15.85 |
$131,127 |
D/D |
(8,273) |
600 |
|
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2021-08-10 |
4 |
OE |
$1.44 |
$12,777 |
D/D |
8,873 |
8,873 |
|
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2021-08-09 |
4 |
AS |
$17.18 |
$260,849 |
D/D |
(15,000) |
0 |
|
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2021-08-09 |
4 |
OE |
$1.44 |
$21,600 |
D/D |
15,000 |
15,000 |
|
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2021-07-29 |
4 |
AS |
$17.18 |
$257,700 |
D/D |
(15,000) |
0 |
|
- |
|
| Perfetti Riccardo |
Chief Medical Officer |
• – – |
2021-07-29 |
4 |
OE |
$1.44 |
$21,600 |
D/D |
15,000 |
15,000 |
|
- |
|
154 Records found
|
|
Page 1 of 7 |
|
|
